Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [PMID: 36185717 DOI: 10.4254/wjh.v14.i9.1718]
Corresponding Author of This Article
Katie Shen, MD, Doctor, Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States. shenk2@ccf.org
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Sep 27, 2022; 14(9): 1718-1729 Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1718
Therapies for non-alcoholic fatty liver disease: A 2022 update
Katie Shen, Achintya D Singh, Jamak Modaresi Esfeh, Jamile Wakim-Fleming
Katie Shen, Achintya D Singh, Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Jamak Modaresi Esfeh, Jamile Wakim-Fleming, Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: Shen K and Singh AD contributed to paper design, primary analysis, manuscript writing; Shen K contributed to literature review; Modaresi Esfeh J and Wakim-Fleming F contributed to critical revisions; all authors have made a significant contribution to this study and have approved the final manuscript.
Conflict-of-interest statement: There are no conflicts of interest or supportive foundations to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Katie Shen, MD, Doctor, Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States. shenk2@ccf.org
Received: May 19, 2022 Peer-review started: May 19, 2022 First decision: June 9, 2022 Revised: June 22, 2022 Accepted: August 16, 2022 Article in press: August 16, 2022 Published online: September 27, 2022 Processing time: 126 Days and 7.6 Hours
Abstract
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development.
Core Tip: Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic with high morbidity and mortality. Although lifestyle modifications will remain a cornerstone of disease management, a multitude of therapies are under development that target different aspects of NAFLD pathogenesis.
